This is a working overview of deamidation, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-24 and is reviewed periodically as new material appears.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized or solid form |
| Solubility | Sparingly soluble in water | May require buffer or pH adjustment |
| Typical storage temperature | 2–8 °C | Refrigerated; protect from light |
| Common analytical method | RP-HPLC | For purity and impurity profiling |
| Molecular weight | Approximately 4813 Da | For the peptide backbone; varies with counterions |
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Niacin is incorporated into multi-vitamin and sold as a single-ingredient dietary supplement. The latter can be immediate or slow release. Nicotinamide is used to treat niacin deficiency and for supplementation because it does not cause the flushing adverse reaction seen with nicotinic acid. Nicotinamide may be toxic to the liver at doses exceeding 3 g/day for adults. One form of dietary supplement sold in the US is inositol hexanicotinate (IHN), also called inositol nicotinate. This is inositol that has been esterified with niacin on all six of inositol's alcohol groups. IHN is usually sold as "flush-free" or "no-flush" niacin in units of 250, 500, or 1000 mg/tablets or capsules. In the US, it is sold as an over-the-counter formulation, and often is marketed and labeled as niacin, thus misleading consumers into thinking they are getting an active form of the medication. While this form of niacin does not cause the flushing associated with the immediate-release products, there is not enough evidence to recommend IHN to treat hyperlipidemia.
In February 2020, Marguerite Stern, alongside Christine Delphy and Fatiha Agag-Boudjahlat, co-signed a column written by Pauline Arrighi entitled "Trans: suffit-il de s'autoproclamer femme pour pouvoir exiger d'être considéré comme telle?" ("Trans: is it enough to proclaim oneself a woman to be able to demand to be considered as such"). This column was initially published in HuffPost and later taken town the editorial staff, who described it as transphobic. It was later republished by Marianne. On February 26, 2020, several personalities and associations signed two columns in Libération entitled "Féminisme: le débat sur la place des femmes trans n'a pas lieu d'être" ("Feminism: the debate on the place of trans women has no place") and "À toi ma sœur, mon frère, mon adelphe" ("To you my sister, my brother, my sibling"). These opposed pieces crystallized the ongoing dissension within the collage movement over transgender rights. Marguerite Stern was harassed for her positions, and received death threats, which led to psychiatric hospitalization for generalized anxiety disorder. In September 2021, seven authors responded to these views by withdrawing from a feminist book fair due to Stern and fellow activist Dora Moutot's participation. In August 2022, she co-signed with Dora Moutot a column published in Marianne addressed to Élisabeth Borne, in which they opposed a Planned Parenthood poster with a pregnant transgender man, stating that "it uses vocabulary used by transactivists".
=== 1970s === 1970: Australian geologist and palaeontologist Dorothy Hill became the first female president of the Australian Academy of Science. 1970: New Zealand geologist and palynologist Rosemary Askin the first New Zealand woman to undertake her own research programme in Antarctica. 1970: Spanish biochemist Margarita Salas discovered and characterized the Φ29 phage DNA polymerase. She was also the first scientific woman elected to the Royal Spanish Academy and was the first woman recipient of the Carlos J. Finlay Prize for Microbiology. 1970: Samira Islam became the first Saudi Arabian person to earn a PhD in pharmacology. 1970: American astronomer Vera Rubin published the first evidence for dark matter. 1970: Polish geologist Franciszka Szymakowska became widely known because of her unique and detailed geological drawings that are still used today. 1971: Romanian chemist Ecaterina Ciorănescu-Nenițescu became a member of the New York Chemical Society. She was noted for developing synthesis processes for antituberculosis drugs and insecticides and creating new substances using cytostatic grafting. 1973: American physicist Anna Coble became the first African-American woman to receive a PhD in biophysics, completing her dissertation at University of Illinois. 1974: Dominican marine biologist Idelisa Bonnelly founded the Dominican Republic Academy of Science. 1975: Indian chemist Asima Chatterjee was elected the General President of the Indian Science Congress Association. She simultaneously became the first female scientist ever elected a member of the congress.
Lord Advocate Dorothy Bain, Scotland's most senior lawyer, apologises to victims of the Post Office scandal, saying they were let down by the justice system. Finance Secretary Shona Robison confirms that the Scottish Government is to cut at least 1,200 funded university places as they cannot afford to continue paying for additional places created during the COVID-19 pandemic. 17 January – The UK government is seeking legal expenses from the Scottish Government over its challenge against the veto of the Gender Recognition Reform (Scotland) Bill. 18 January – Community Safety Minister Siobhian Brown announces that Scotland will introduce legislation to ban the sale, breeding and abandonment of American XL bully dogs, replicating the law for England and Wales, at a date to be confirmed later. Nuns Sister Sarah McDermott and Sister Eileen Igoe, and carer Margaret Hughes, who mistreated children at Smyllum Park, an orphanage in Lanark from 1969 until 1981 when it closed, are each sentenced to three years in prison. Helen Goss, the mother of an eleven-year-old girl from Aberdeenshire with long COVID, launches legal action against NHS Grampian for what she says are the health board's "multiple failings" in the care and treatment of her daughter. 21 January – Scotland's First Minister, Humza Yousaf, tells the BBC's Sunday with Laura Kuenssberg he is willing to work with Sir Keir Starmer if he becomes prime minister after the next general election. ScotRail cancels all services from 7pm until after the following day's rush hour because of high winds caused by Storm Isha.
Sources: en.wikipedia.org
During this time period, insurance companies realized the connection between weight and life expectancy and increased premiums for the obese. Many cultures throughout history have viewed obesity as the result of a character flaw. The obesus or fat character in Ancient Greek comedy was a glutton and figure of mockery. During Christian times, food was viewed as a gateway to the sins of sloth and lust. In modern Western culture, excess weight is often regarded as unattractive, and obesity is commonly associated with various negative stereotypes. People of all ages can face social stigmatization and may be targeted by bullies or shunned by their peers. Public perceptions in Western society regarding healthy body weight differ from those regarding the weight that is considered ideal – and both have changed since the beginning of the 20th century. The weight that is viewed as an ideal has become lower since the 1920s. This is illustrated by the fact that the average height of Miss America pageant winners increased by 2% from 1922 to 1999, while their average weight decreased by 12%. On the other hand, people's views concerning healthy weight have changed in the opposite direction. In Britain, the weight at which people considered themselves to be overweight was significantly higher in 2007 than in 1999. These changes are believed to be due to increasing rates of adiposity leading to increased acceptance of extra body fat as being normal. Obesity is still seen as a sign of wealth and well-being in many parts of Africa.
== Chivalric orders == Kingdom of Prussia: Knight of the Black Eagle, 27 January 1897; with Collar, 1904 Knight of the Royal Crown Order, 1st Class, 27 January 1897 Grand Commander's Cross of the Royal House Order of Hohenzollern, 27 January 1897 Grand Cross of the Red Eagle, with Crown, 29 January 1897 Denmark: Knight of the Elephant, 15 June 1912 Grand Duchy of Hesse: Grand Cross of the Ludwig Order, 27 January 1909 Hohenzollern: Cross of Honour of the Princely House Order of Hohenzollern, 1st Class Mecklenburg: Grand Cross of the Wendish Crown Netherlands: Grand Cross of the Netherlands Lion Ottoman Empire: Order of Osmanieh, 1st Class with Star in Diamonds
Cystathionine is an intermediate in the synthesis of cysteine from homocysteine. It is produced by the transsulfuration pathway and is converted into cysteine by cystathionine gamma-lyase (CTH). Biosynthetically, cystathionine is generated from homocysteine and serine by cystathionine beta synthase (upper reaction in the diagram below). It is then cleaved into cysteine and α-ketobutyrate by cystathionine gamma-lyase (lower reaction). An excess of cystathionine in the urine is called cystathioninuria.
Sources: en.wikipedia.org
RP-HPLC is widely used for purity and impurity profiling. Mass spectrometry confirms identity.
Typically refrigerated at 2–8 °C. Protect from light and avoid freezing.
Deamidation, oxidation, and aggregation products. SEC and ion-exchange chromatography are used.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.